CCN2 and idiopathic pulmonary fibrosis: The clinical trial of F3019, a human monoclonal anti-CTGF antibody, demonstrated that the blockage of CTGF was safe and well tolerated in IPF and was effective in some patients with IPF (Raghu et al., 2016).